Supernus Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Rockville, Maryland, focused on developing and commercializing products for the treatment of central nervous system disorders, particularly epilepsy and ADHD. The company was founded in 2005 as a spin-off from Noven Pharmaceuticals.

Overview

flowchart TD
    companies_supernus_pharmaceuti["Supernus Pharmaceuticals"]
    companies_supernus_pharmaceuti["biopharmaceutical"]
    companies_supernus_pharmaceuti -->|"related to"| companies_supernus_pharmaceuti
    style companies_supernus_pharmaceuti fill:#81c784,stroke:#333,color:#000
    companies_supernus_pharmaceuti["company"]
    companies_supernus_pharmaceuti -->|"related to"| companies_supernus_pharmaceuti
    style companies_supernus_pharmaceuti fill:#81c784,stroke:#333,color:#000
    companies_supernus_pharmaceuti["headquartered"]
    companies_supernus_pharmaceuti -->|"related to"| companies_supernus_pharmaceuti
    style companies_supernus_pharmaceuti fill:#81c784,stroke:#333,color:#000
    companies_supernus_pharmaceuti["Rockville"]
    companies_supernus_pharmaceuti -->|"related to"| companies_supernus_pharmaceuti
    style companies_supernus_pharmaceuti fill:#81c784,stroke:#333,color:#000
    style companies_supernus_pharmaceuti fill:#4fc3f7,stroke:#333,color:#000

Supernus has built a portfolio of approved products for epilepsy and ADHD, and is expanding into movement disorders and other CNS conditions. The company’s strategy focuses on developing differentiated products with improved efficacy and safety profiles compared to existing treatments

Funding

• IPO: 2012 (NASDAQ: SUPN)

• Market Cap: ~$6B (2026)

Corporate Highlights

• Founded: 2005

• Headquarters: Rockville, Maryland

• NASDAQ: SUPN

• Employees: Approximately 700

History and Development

Founding (2005)

Supernus was founded in 2005 as a spin-off from Noven Pharmaceuticals, focusing on CNS disorders with an emphasis on novel formulations of existing drugs.

Growth (2005-2020)

• 2013: FDA approval of OXTELLAR XR and TROKENDI XR for epilepsy

• 2018: Acquisition of epilepsy portfolio including EPIDIOLEX

• 2021: FDA approval of Qelbree (viloxazine) for ADHD

Recent Developments (2021-Present)

• Expanded Parkinson’s disease portfolio with apomorphine products

• Advanced novel pipeline programs in depression and epilepsy

• Focus on treatment-resistant conditions

Approved Products

Epilepsy Portfolio

OXTELLAR XR and TROKENDI XR are extended-release formulations of generic epilepsy drugs, designed to provide improved seizure control with once-daily dosing and more stable blood levels.

Parkinson’s Disease

APOKYN (apomorphine injection) provides rapid rescue from OFF episodes in Parkinson’s disease patients.

Autonomic Dysfunction in Parkinson’s Disease

Supernus’s Parkinson’s disease products address autonomic dysfunction manifestations:

Apomorphine Therapy and Autonomic Function

APOKYN and the SPN-830 continuous infusion address several autonomic aspects of PD:

• OFF-Time Reduction: Reducing “off” episodes decreases catecholamine surges that can exacerbate orthostatic hypotension

• Blood Pressure Stability: Stable dopaminergic stimulation reduces the blood pressure fluctuations seen with oral medication cycling

• GI Symptoms: Reduced OFF episodes may decrease gastroparesis symptoms and improve nutrient absorption

SPN-830 (Continuous Apomorphine Infusion)

The Phase 3 apomorphine infusion program offers particular benefits for autonomic function:

• Continuous Delivery: Maintains stable plasma drug levels, avoiding peaks and troughs that trigger autonomic symptoms

• Sleep Quality: Overnight continuous delivery may reduce nocturnal motor symptoms that disrupt sleep architecture

• Orthostatic Hypotension Management: Stable dopamine levels reduce the risk of medication-induced blood pressure drops

Qelbree (Viloxazine) - Norepinephrine Modulation

While approved for ADHD, viloxazine’s norepinephrine reuptake inhibition has potential applications:

• Autonomic Regulation: Norepinephrine plays a key role in blood pressure regulation through the sympathetic nervous system

• Research Interest: Investigated for autonomic symptoms in PD and related disorders

ADHD Portfolio

Qelbree (Viloxazine): Approved in 2021, Qelbree represents the first non-stimulant ADHD medication approved in over 20 years^{3FDA Press ReleaseOpen reference}.

Pipeline Programs

Clinical Development

Science and Technology

Extended-Release Technology

Supernus’s products leverage extended-release technology to improve patient outcomes:

• Once-daily dosing improves adherence

• More stable blood levels reduce side effects

• Fewer breakthrough seizures in epilepsy

AMPA Receptor Modulation

SPN-820 targets AMPA receptors for treatment-resistant depression:

• Different from SSRI/SNRI mechanisms

• May offer rapid-acting effects similar to ketamine

• Without dissociative side effects

• Novel mechanism for patients who fail multiple antidepressants^{5Nature Reviews Drug DiscoveryDOI 10.1038/s41573-021-00198-1Open reference}

Neurological Relevance

Supernus addresses significant unmet needs in CNS disorders^{6Pipeline OverviewOpen reference}:

Treatment-Resistant Depression

SPN-820 is a novel AMPA receptor modulator with potential for:

• Rapid-acting antidepressant effects (similar to ketamine)

• Without the psychotomimetic side effects of ketamine

• Oral bioavailability

• Potential for sustained response

AMPA receptor modulation represents a novel mechanism beyond current SSRIs/SNRIs and NMDA receptor antagonists.

Parkinson’s Disease OFF Episodes

Despite dopaminergic therapy, Parkinson’s patients experience OFF episodes when medication wears off:

• SPN-830 (continuous apomorphine infusion) provides steady dopamine agonist delivery

• Reduces motor fluctuations

• Improves quality of life

• Continuous subcutaneous infusion maintains stable plasma levels

Epilepsy

Extended-release formulations improve patient outcomes:

• Better medication adherence (once-daily)

• More stable drug levels (fewer breakthrough seizures)

• Reduced side effects

ADHD Non-Stimulant Option

Qelbree provides an alternative for patients who:

• Cannot tolerate stimulant side effects

• Have history of substance abuse

• Have cardiovascular concerns

• Are younger children (6-17 years old)

Financial Highlights (2024)

• Revenue: Approximately $700 million USD

• Market Cap: Approximately $2 billion USD

• R&D Investment: Approximately $150 million USD

• Focus: CNS specialty products

Related Pages

• Epilepsy

• Attention Deficit Hyperactivity Disorder

• Parkinson’s Disease

• Treatment-Resistant Depression

• Dopamine Signaling

• GABA Signaling

• AMPA Signaling

• Norepinephrine Signaling

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

• Dopamine Signaling

• Norepinephrine Signaling

• Autonomic Nervous System

• Apomorphine

• Autonomic Dysfunction in Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways